{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:21:07Z","timestamp":1787242867371,"version":"build-2736575974"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T00:00:00Z","timestamp":1624924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T00:00:00Z","timestamp":1624924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s10067-021-05767-8","type":"journal-article","created":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T22:02:49Z","timestamp":1624917769000},"page":"4977-4982","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Perspectives on glucocorticoid usage in patients with adult inflammatory myopathy"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1352-9539","authenticated-orcid":false,"given":"Jes\u00fas","family":"Loarce-Martos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9230-4137","authenticated-orcid":false,"given":"James B.","family":"Lilleker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eve","family":"Alder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo","family":"Goode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6492-1288","authenticated-orcid":false,"given":"Hector","family":"Chinoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,29]]},"reference":[{"key":"5767_CR1","doi-asserted-by":"publisher","first-page":"e000784","DOI":"10.1136\/rmdopen-2018-000784","volume":"4","author":"A Meyer","year":"2018","unstructured":"Meyer A, Scir\u00e8 CA, Talarico R et al (2018) Idiopathic inflammatory myopathies: state of the art on clinical practice guidelines [corrected]. RMD Open 4:e000784. https:\/\/doi.org\/10.1136\/rmdopen-2018-000784","journal-title":"RMD Open"},{"key":"5767_CR2","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/nrrheum.2018.42","volume":"14","author":"CV Oddis","year":"2018","unstructured":"Oddis CV, Aggarwal R (2018) Treatment in myositis Nat Rev Rheumatol 14:279\u2013289","journal-title":"Nat Rev Rheumatol"},{"key":"5767_CR3","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1136\/annrheumdis-2015-208916","volume":"75","author":"C Strehl","year":"2016","unstructured":"Strehl C, Bijlsma JWJ, de Wit M et al (2016) Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. Ann Rheum Dis 75:952\u2013957. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208916","journal-title":"Ann Rheum Dis"},{"key":"5767_CR4","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1136\/annrheumdis-2012-202021","volume":"71","author":"WG Dixon","year":"2012","unstructured":"Dixon WG, Bansback N (2012) Understanding the side effects of glucocorticoid therapy: shining a light on a drug everyone thinks they know. Ann Rheum Dis 71:1761\u20131764. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202021","journal-title":"Ann Rheum Dis"},{"key":"5767_CR5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12955-017-0609-9","volume":"15","author":"SD Mathias","year":"2017","unstructured":"Mathias SD, Berry P, De Vries J et al (2017) Development of the Systemic Lupus Erythematosus Steroid Questionnaire (SSQ): a novel patient-reported outcome tool to assess the impact of oral steroid treatment. Health Qual Life Outcomes 15:43. https:\/\/doi.org\/10.1186\/s12955-017-0609-9","journal-title":"Health Qual Life Outcomes"},{"key":"5767_CR6","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/S00296-017-3855-6","volume":"38","author":"JC Robson","year":"2018","unstructured":"Robson JC, Dawson J, Cronholm PF et al (2018) Patient perceptions of glucocorticoids in anti-neutrophil cytoplasmic antibody-associated vasculitis. Rheumatol Int 38:675. https:\/\/doi.org\/10.1007\/S00296-017-3855-6","journal-title":"Rheumatol Int"},{"key":"5767_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/rap\/rky003","volume":"2","author":"TCR McDonnell","year":"2018","unstructured":"McDonnell TCR, Wincup C, Rahman A, Giles I (2018) Going viral in rheumatology: using social media to show that mechanistic research is relevant to patients with lupus and antiphospholipid syndrome. Rheumatol Adv Pract 2:1\u20136. https:\/\/doi.org\/10.1093\/rap\/rky003","journal-title":"Rheumatol Adv Pract"},{"key":"5767_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11234","author":"G Venter","year":"2021","unstructured":"Venter G, Tieu J, Black R et al (2021) Perspectives of glucocorticoid use in patients with rheumatoid arthritis. ACR open Rheumatol. https:\/\/doi.org\/10.1002\/acr2.11234","journal-title":"ACR open Rheumatol"},{"key":"5767_CR9","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1093\/rheumatology\/kew421","volume":"56","author":"R Costello","year":"2017","unstructured":"Costello R, Patel R, Humphreys J et al (2017) Timing of glucocorticoid administration: a cross-sectional survey of glucocorticoid users in an online social network for health. Rheumatology (Oxford) 56:494\u2013495. https:\/\/doi.org\/10.1093\/rheumatology\/kew421","journal-title":"Rheumatology (Oxford)"},{"key":"5767_CR10","unstructured":"Home - Myositis UK. https:\/\/www.myositis.org.uk\/. Accessed 7 Apr 2021"},{"key":"5767_CR11","doi-asserted-by":"publisher","unstructured":"Roubille C, Coffy A, Rincheval N, et al (2021) Ten-year analysis of the risk of severe outcomes related to low-dose glucocorticoids in early rheumatoid arthritis. Rheumatology. https:\/\/doi.org\/10.1093\/rheumatology\/keaa850","DOI":"10.1093\/rheumatology\/keaa850"},{"key":"5767_CR12","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1093\/rheumatology\/keaa459","volume":"60","author":"J Lim","year":"2021","unstructured":"Lim J, Eftimov F, Verhamme C et al (2021) Intravenous immunoglobulins as first-line treatment in idiopathic inflammatory myopathies: a pilot study. Rheumatology 60:1784\u20131792. https:\/\/doi.org\/10.1093\/rheumatology\/keaa459","journal-title":"Rheumatology"},{"key":"5767_CR13","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1136\/annrheumdis-2017-212047","volume":"77","author":"R Aggarwal","year":"2018","unstructured":"Aggarwal R, Marder G, Koontz DC et al (2018) Efficacy and safety of adrenocorticotropic hormone gel in refractory dermatomyositis and polymyositis. Ann Rheum Dis 77:720\u2013727. https:\/\/doi.org\/10.1136\/annrheumdis-2017-212047","journal-title":"Ann Rheum Dis"},{"key":"5767_CR14","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1136\/annrheumdis-2017-211868","volume":"77","author":"JB Lilleker","year":"2018","unstructured":"Lilleker JB, Vencovsky J, Wang G et al (2018) The EuroMyositis registry: an international collaborative tool to facilitate myositis research. Ann Rheum Dis 77:30\u201339. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211868","journal-title":"Ann Rheum Dis"},{"key":"5767_CR15","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1007\/s10067-009-1181-4","volume":"28","author":"KP Ng","year":"2009","unstructured":"Ng KP, Ramos F, Sultan SM, Isenberg DA (2009) Concomitant diseases in a cohort of patients with idiopathic myositis during long-term follow-up. Clin Rheumatol 28:947\u2013953. https:\/\/doi.org\/10.1007\/s10067-009-1181-4","journal-title":"Clin Rheumatol"},{"key":"5767_CR16","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jbspin.2013.07.001","volume":"81","author":"K Nassar","year":"2014","unstructured":"Nassar K, Janani S, Roux C et al (2014) Long-term systemic glucocorticoid therapy: Patients\u2019 representations, prescribers\u2019 perceptions, and treatment adherence. Jt Bone Spine 81:64\u201368. https:\/\/doi.org\/10.1016\/j.jbspin.2013.07.001","journal-title":"Jt Bone Spine"},{"key":"5767_CR17","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1097\/RHU.0000000000000585","volume":"23","author":"RJ Black","year":"2017","unstructured":"Black RJ, Goodman SM, Ruediger C et al (2017) A survey of glucocorticoid adverse effects and benefits in rheumatic diseases: the patient perspective. J Clin Rheumatol 23:416\u2013420. https:\/\/doi.org\/10.1097\/RHU.0000000000000585","journal-title":"J Clin Rheumatol"},{"key":"5767_CR18","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1111\/j.1365-2133.2010.09877.x","volume":"163","author":"C Arena","year":"2010","unstructured":"Arena C, Morin AS, Blanchon T et al (2010) Impact of glucocorticoid-induced adverse events on adherence in patients receiving long-term systemic glucocorticoid therapy. Br J Dermatol 163:832\u2013837. https:\/\/doi.org\/10.1111\/j.1365-2133.2010.09877.x","journal-title":"Br J Dermatol"},{"key":"5767_CR19","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1136\/annrheumdis-2013-203249","volume":"72","author":"N Duru","year":"2013","unstructured":"Duru N, Van Der Goes MC, Jacobs JWG et al (2013) EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 72:1905\u20131913. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203249","journal-title":"Ann Rheum Dis"},{"key":"5767_CR20","doi-asserted-by":"publisher","unstructured":"Santiago T, Voshaar M, de Wit M, et al (2021) Patients\u2019 and rheumatologists\u2019 perspectives on the efficacy and safety of low-dose glucocorticoids in rheumatoid arthritis\u2014an international survey within the GLORIA study. Rheumatology 1\u20139. https:\/\/doi.org\/10.1093\/rheumatology\/keaa785","DOI":"10.1093\/rheumatology\/keaa785"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05767-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-021-05767-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05767-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T20:03:28Z","timestamp":1637179408000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-021-05767-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,29]]},"references-count":20,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["5767"],"URL":"https:\/\/doi.org\/10.1007\/s10067-021-05767-8","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,29]]},"assertion":[{"value":"4 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Health Research Authority decision tools (\n                      \n                      ) were determined that ethical approval\/consent was not required for the anonymous survey.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The Health Research Authority decision tools (\n                      \n                      ) were determined that ethical approval\/consent was not required for the anonymous survey.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}